Vrije Universiteit Brussel’s Camel-IDS collected funding from investors including Novo for a radiation-based oncology platform that will initially target Her2-positive brain metastatic breast cancer.

Camel-IDS, a Belgium-based radioimmunotherapy spinout from Vrije Universiteit Brussel, has attracted €37m ($42m) in a series A round co-led by Novo Seeds, a corporate venturing subsidiary of pharmaceutical firm Novo.

Venture capital firms V-Bio Ventures, Gimv, HealthCap, Pontifax and BioMedPartners also co-led the round. It followed $1.5m of seed funding from investors including nonprofit research body Fournier-Majoie Foundation at an unspecified date.

Founded in 2014, Camel-IDS is working on immunotherapeutic drugs activated by radiation that utilise antigen-binding fragments derived from…